Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for ophthalmic diseases. Its lead product, KIO-301, is a potential vision-restoring small molecule in Phase 2 trials for retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal immuno-modulatory small-molecule inhibitor of dihydroorotate dehydrogenase, in a Phase 1b/2a study for posterior non-infectious uveitis and in pre-clinical development for proliferative vitreoretinopathy, and KIO-101, an eye drop formulation for the ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for KIO-301. The company operates in the United States, Austria, and Australia. It was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Incorporated in 1998, it is headquartered in Encinitas, California.